Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-710-0 | CAS number: 7695-91-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The NOAEL of 500 mg/kg bw/day was based on a well conducted 90-day study in rat comparable to OECD guideline 408 (Abdo, 1986).
The following repeated studies were also part of the assessment for this endpoint:
28-day studies: BASF (1983); feed study in rats (OECD 407) and a feed study in dogs (dosing stopped after 28 day in an OECD 409 comparable study ; BASF,1982), Pfister (1999); study oral gavage in rats (GLP and OECD 407).
90-day study: Pfannkuch (2000); oral gavage study in minipigs (GLP and OECD 409), supplemented with vitamin K ,
2 -year study : Wheldon (1978); feed study in rats (OECD 453) supplemented with Vitamin K
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
Additional information
A reliable (GLP, OECD 407) 28 day study in rat (Pfister, DSM;1999) was available . The rats were treated by oral gavage at 180, 600 and 2000 mg/kg bw day. As no treatment-related findings were noted, the NOAEL in this study was set at 2000 mg/kg.
The finding in this study was supported by another 28-day study feed study dogs (BASF; 1982). The dogs were treated at ca. 45, 90, 180 and 360 mg/kg bw/day. The test substance was well tolerated. No clinical signs of toxicity and no deaths were observed. Body weight, food consumption, and clinical chemical, hematological, and urine parameters were not altered. There were no gross/histopathological changes in any group. In this study the NOAEL was set at >360 mg/kg in the dog study.
A 90-day repeated dose (oral gavage) study was available (Abdo et al. 1986). In this study the rats were dosed at 125, 500 and 2000 mg/kg. The relative liver weight was significantly increased in high dose females. Administration of 2000 mg/kg bw/d caused hematological changes: prolongation of prothrombin and activated partial thromboblastin (APTT) times and an increase in fibrinogen value, reticulocytosis and a decrease in hematocrit values and hemoglobin concentrations was observed in males; APTT times were also increased in females. Hemorrhagic diathesis was observed in males and females of the high dose group; and increased medullary erythropoiesis was seen in the spleen of one high dose male.
The test substance at all dose levels tested caused interstitial inflammation and adenomatous hyperplasia of the lung. The lung lesions were observed in all vitamin E-treated groups, and the incidence and severity increased in a dose-dependent manner. These lesions were characterized by increased cellularity, vascular congestion, thickened alveolar walls and the presence of foamy macrophages (some of which had undergone cell death and degeneration) in the alveolar spaces. A lipid-like yellow pigmentation was often present within either the macrophages or alveoli. These effects were attributed (as in the other oral gavage 90-day in minipigs study) to local aspiration of the test substance, which would not occur under normal circumstances. Furthermore, these effects were not seen in the chronic feed study (Wheldon, 1978). Therefore, for the NOAEL derivation the effects in the lungs were not considered.
Because at 500 mg/kg only APTT values were increased in absence of an increase in PT and fibrinogen value, the NOAEL is set at 500 mg/kg.
Another reliable (GLP, OECD 409) 90-day study in minipigs (Pfannkuch, DSM; 2000) was available. The minipigs were dosed by oral gavage at 180, 600 and 2000 mg/kg day. In this study prolonged activated partial thromoplastin time was attributed to the suboptimal supplementation of Vitamin K. Also in this study effects in the lungs were seen; macroscopically as firm/grey nodules in the lungs and massive locally extensive to diffuse chronic necrotizing granulomatous pneumonia. These changes were considered to be a local reaction to the aspiration of test substance into the lungs that would not occur under conditions of normal use. Due to the Vitamin K supplementation a NOAEL could not be derived.
In a repeated dose toxicity study rats were fed DL-Alpha-Tocopheryl acetate at dietary concentrations providing dosages of 0, 500, 1000 and 2000 mg/kg bw/d for 104 weeks (Wheldon et al., 1983). Vitamin K supplementation suppressed the induced hypoprothrombinemia. Growth rate and survival were unaltered by treatment. The observation of agglomerations of vacuolated macrophages in the hepatic centriacini in all treatment groups, alongside changes in serum liver enzyme activity, suggested a limited hepatic response to vitamin E overload. A NOAEL could not be established, since hemorrhage effects were treated by supplementing Vitamin K after 26 weeks.
For the DNEL-derivation a NOAEL of 500 mg/kg bw derived from the 90-day repeated dose study (Abdo, 1986) will be used.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: blood coagulation
Justification for classification or non-classification
According to EU Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 classification is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.